跳至主要内容
临床试验/NCT05939882
NCT05939882招募中不适用

A Double-blind, Randomized Controlled Study of Low Concentration Atropine in the Prevention of Myopia in Pre-myopia Children.

Shanghai Eye Disease Prevention and Treatment Center1 个研究点 分布在 1 个国家目标入组 428 人开始时间: 2023年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
428
试验地点
1
主要终点
Cumulative Incidence of Myopia

研究概览

简要总结

This double-blind, randomized controlled clinical study is to evaluate the effectiveness and safety of low concentration atropine in preventing myopia in pre-myopia children, and to explore whether there is a dose effect relationship between different concentrations of atropine in preventing myopia.

详细描述

The main questions this double-blind, randomized controlled clinical study aims to answer are:

  1. To evaluate the effect of low concentration atropine on the incidence of myopia in pre myopia children.
  2. To evaluate the effectiveness of low concentration atropine in controlling refractive and axial progression.

Patients are randomly divided into three treatment groups with different atropine concentrations(0.01%, 0.02%, 0.04%) and one control group with atropine dissolvant. Patients are required to use the eye drops every night for one year and record after daily usage.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
6 Years 至 9 Years(Child)
性别
All
接受健康志愿者

入选标准

  • The age of the screening stage is 6-9 years, both sexes;
  • One eye met the diagnosis of pre-myopia, the spherical equivalent was between -0.50D and +0.75D, the astigmatism was ≥-1.50D, and the best corrected far vision was at least 1.0;
  • At least one of parents suffers from myopia (SE of at least one eye <=-3.00D);
  • Parents have signed informed consent and agree to participate in screening and follow-up.

排除标准

  • Parents disagree to sign the informed consent;
  • Presence of strabismus, amblyopia, or other ocular abnormalities, or have a history of eye surgery;
  • Presence of other eye or systemic diseases;
  • Allergies to low concentration atropine or sulfuric acid drugs;
  • Histories of using other preventive measures, such as using red light within 6 months or atropine within 1 month;
  • Presence of other situations that the researchers think is not appropriate for patients to be included in the project.

研究组 & 干预措施

placebo

Placebo Comparator

placebo eye drop

干预措施: Placebo (Drug)

0.04% atropine

Experimental

0.04% atropine eye drop

干预措施: low concentration atropine (0.04%) (Drug)

0.01% atropine

Experimental

0.01% atropine eye drop

干预措施: low concentration atropine (0.01%) (Drug)

0.02% atropine

Experimental

0.02% atropine eye drop

干预措施: low concentration atropine (0.02%) (Drug)

结局指标

主要结局

Cumulative Incidence of Myopia

时间窗: 1 year

Effectiveness Evaluation

次要结局

  • Changes in visual acuity(1 year)
  • Changes in Choroidal Thickness(1 year)
  • Changes in SE (after cycloplegia)(1 year)
  • Changes in AL(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验